Investor's Business Daily - Investing RSS http://ift.tt/1HH35cg Drug stocks took hard hits Wednesday and Jazz Pharmaceuticals (JAZZ) was no exception. A sharp drop put shares back below a 177.11 buy point and in a test of its 50-day moving average. Investors who bought at the higher 183.94 entry faced a sell signal as the stock slipped as much as 7% below the entry. The stock has now largely given up gains from a seven-session run-up that started March 12. It broke out past its 177.11 buy point in late
No comments:
Post a Comment